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ABSTRACT
Receptor-PI3K-mTORC1 signaling and fatty acid synthase (FASN)-regulated 
lipid biosynthesis harbor numerous drug targets and are molecularly connected. We 
hypothesize that unraveling the mechanisms of pathway cross-talk will be useful for 
designing novel co-targeting strategies for ovarian cancer (OC). The impact of receptor-
PI3K-mTORC1 onto FASN is already well-characterized. However, reverse actions–from 
FASN towards receptor-PI3K-mTORC1–are still elusive. We show that FASN-blockade 
impairs receptor-PI3K-mTORC1 signaling at multiple levels. Thin-layer chromatography 
and MALDI-MS/MS reveals that FASN-inhibitors (C75, G28UCM) augment polyunsaturated 
fatty acids and diminish signaling lipids diacylglycerol (DAG) and phosphatidylinositol 
3,4,5-trisphosphate (PIP3) in OC cells (SKOV3, OVCAR-3, A2780, HOC-7). Western 
blotting and micropatterning demonstrate that FASN-blockers impair phosphorylation/
expression of EGF-receptor/ERBB/HER and decrease GRB2–EGF-receptor recruitment 
leading to PI3K-AKT suppression. FASN-inhibitors activate stress response-genes  
HIF-1α-REDD1 (RTP801/DIG2/DDIT4) and AMPKα causing mTORC1- and S6-repression. 
We conclude that FASN-inhibitor-mediated blockade of receptor-PI3K-mTORC1 
occurs due to a number of distinct but cooperating processes. Moreover, decrease of  
PI3K-mTORC1 abolishes cross-repression of MEK-ERK causing ERK activation. 
Consequently, the MEK-inhibitor selumetinib/AZD6244, in contrast to the PI3K/mTOR-
inhibitor dactolisib/NVP-BEZ235, increases growth inhibition when given together with 
a FASN-blocker. We are the first to provide deep insight on how FASN-inhibition blocks  
ERBB-PI3K-mTORC1 activity at multiple molecular levels. Moreover, our data encourage 
therapeutic approaches using FASN-antagonists together with MEK-ERK-inhibitors.
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INTRODUCTION
Ovarian cancer (OC) represents the most 
lethal malignancy of the female reproductive system 
[1–3]. Although new anticancer drugs have significantly 
improved the five-year survival of OC, overall mortality yet 
remains invariably high [4]. Thus, a deeper understanding 
of the molecular background of OC is required. Many 
OCs harbor hyperactive oncogenic drivers in the ERBB-
phosphatidylinositol 3-kinase(PI3K)-mechanistic target 
of rapamycin complex 1 (mTORC1) signaling pathway. 
They exhibit ‘PI3Kness’ and are sensitive to drugs 
that target this pathway [5, 6]. ERBB-PI3K-mTORC1 
controls diverse cellular functions including proliferation, 
survival, growth, migration, autophagy, angiogenesis, 
metabolism, and energy balance [7]. At the molecular 
level, ERBB membrane receptors activate PI3K, which 
converts phosphatidylinositol 4,5-bisphosphate (PIP2) 
to phosphatidylinositol 3,4,5-trisphosphate (PIP3). 
PIP3 stimulates AKT, which then inactivates TSC2 [8]. 
Thereby, the TSC1/2 tumor suppressor complex loses 
its ability to block RHEB–the upstream activator of 
mTORC1–and enables mTORC1 downstream signaling. 
S6K1 and 4EBP1 are the main targets of mTORC1 and 
control cell division and protein biosynthesis. TSC1/2 
functions as a regulator of cell homeostasis. It receives 
activating inputs from REDD1 (DDIT4, RTP801) and 
AMPK–two sensors of nutritive and energetic shortage, 
which counteract AKT-mediated induction of mTORC1 
and block cell proliferation.
Cancer cells require large amounts of proteins, 
nucleotides, lipids and energy for growth. In recent 
years, the reprogramming occurring in cancer 
cell metabolic networks has gained considerable 
attention. Research in this field will likely generate 
new concepts for improved anticancer treatment. 
For instance, lipid biosynthesis has been found to be 
hyperactive in most malignant tissues. Hence, fatty 
acid synthase (FASN), the enzyme responsible for 
de novo lipogenesis, is overexpressed in tumors including 
OC and is considered a useful tumor marker. It signifies 
unfavorable outcome and represents a hallmark of 
cancer [9–12]. At the biochemical level, acetyl-CoA is 
generated from citrate and is further processed to malonyl-
CoA. Both CoA-conjugates are used by FASN to form 
the saturated long-chain fatty acid palmitic acid (PA; 
16 : 0) [10]. Blockade of FASN has been demonstrated 
to exert anticancer effects in human OC [11] and thus 
represents an appealing strategy for treatment.
Available data suggest that ERBB-PI3K-mTORC1 
up-regulates FASN by induction of the transcription 
factor SREBP-1c [13]. We recently demonstrated that 
FASN in turn can stimulate PI3K-mTORC1 signaling and 
contrariwise blockade of FASN impairs PI3K-mTORC1 
[14, 15]. However, the mechanisms of this inhibitory action 
from FASN onto ERBB-PI3K-mTORC1 remain elusive. 
Here we demonstrate that blockade of FASN activates 
the mTORC1 repressors REDD1 and AMPKα causing 
mTORC1 downstream inhibition. This is accompanied 
by compensatory MAPK ERK activation. Accordingly, 
combination of' FASN-blockers with MAPK pathway 
inhibitors yields stronger growth inhibition than single 
FASN-inhibitor treatment. Herewith, we provide the first 
in-depth analysis on how FASN-inhibition blocks ERBB-
PI3K-mTORC1 activity at various molecular levels.
RESULTS
OC cell lines reveal diverse sensitivities against 
FASN-inhibitors
We and others have shown that FASN-inhibitor 
sensitivities and FASN protein expression levels correlate 
with each other, while differing markedly between 
individual OC cell lines [12–16]. Thus, the IC
50 
values for 
growth inhibition after 72 h exposure to the prototypic 
FASN-inhibitor C75 or to the more advanced compound 
G28UCM vary considerably in the cell lines used (IC
50
 
of C75: HOC-7 = 29 ± 1 µM, SKOV3 = 27 ± 5 µM, 
OVCAR-3 = 18 ± 3 µM, A2780 = 22 ± 5 µM; IC
50
 of 
G28UCM: HOC-7 = 21 ± 1 µM, SKOV3 = 10 ± 3 µM, 
OVCAR-3 = 4 ± 1 µM, A2780 = 3 ± 1 µM) (Supplementary 
Figure 1). Therefore, isoeffective instead of identical drug 
concentrations have to be used for comparison of FASN-
inhibitor effects in different cell lines. For instance, 72 h of 
exposure to 40, 25, 20 or 10 µM G28UCM, or to 40, 35, 
20 or 30 µM C75 yield roughly similar growth inhibition 
(60–70 %) in SKOV3, HOC-7, OVCAR-3 or A2780 cells, 
respectively.
FASN-inhibitors down-regulate oleic acid (OA), 
diacylglycerol (DAG) and phosphatidylinositol 
3,4,5-trisphosphate (PIP3), but elevate 
polyunsaturated fatty acids (PUFA) and 
malonyl-CoA
Acetyl-CoA carboxylase converts acetyl-CoA to 
malonyl-CoA. Both intermediates are used by FASN to 
generate the saturated fatty acid (FA) palmitic acid (PA 
(16 : 0)), which is the source for most other lipids including 
monounsaturated FA (MUFA) oleic acid (OA (18 : 1(9Z))). 
Blockade of FASN therefore leads to loss of FAs and to 
accumulation of malonyl-CoA (Figure 1A). Both conditions 
can be harmful to the cells [17]. We demonstrate that addition 
of exogenous OA, unlike PA, partially abolishes FASN-
inhibitor-mediated growth arrest and apoptosis (Figure 1B, 
1C). Inhibitors of acetyl-CoA carboxylase such as TOFA, on 
the other hand, induce FA deficiency without accumulation 
of malonyl-CoA and impair OC cell growth only at very 
high concentrations (Figure 1D). These data suggest that 
cytotoxicity of FASN-blockers is most likely mediated by 
both OA deprivation and malonyl-CoA accumulation. 
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Next we applied thin-layer chromatography for 
mapping the effects of FASN-inhibition on the major lipid 
classes. DAG is formed by cleavage of phosphatidylinositol 
4,5-bisphosphate (PIP2) [18] and transfers signals from 
membrane receptors to protein kinase C (PKC). DAG 
is also a precursor of membrane glycerophospholipids 
and plays a key role in de novo lipogenesis and lipid 
remodeling in cancer [19]. Interestingly, DAG levels 
are decreased after 8 h of exposure to G28UCM (−54% 
in SKOV3, −5% in OVCAR-3). This is followed by a 
transient rebound at 24 h (+65% in SKOV3, +15% in 
OVCAR-3) and a subsequent decline leading to severe 
depletion at 72 h (−70% in SKOV3, −67% in OVCAR-3) 
(Figure 2). A similar down-regulation of DAG is also seen 
when cells are exposed to C75, the other FASN-inhibitor 
(Supplementary Figure 2). Our data corroborate recent 
findings [20] demonstrating that downregulation of DAG 
is essential for growth inhibition by FASN-inhibitors.
While oncogenic functions of FASN, DAG, PKC, 
PIPs, and PI3K-mTORC1 have already been demonstrated, 
the influence of FASN(-inhibitors) on phosphatidylinositol 
(PI) metabolism and signaling in cancer is still unknown 
[10, 21–23]. To address these issues we employed a matrix-
assisted laser desorption/ionization (MALDI)-hybrid 
quadrupole iontrap (QIT)-time-of-flight (TOF)-tandem-
mass spectrometry(MS/MS) based lipidomics screening 
approach [24]. A transient rise of total PI after 8 h treatment 
with G28UCM is followed by a sharp decline (Figure 3A, 
3B). PI regulation is seen with both inhibitors in both cell 
lines, albeit it is less pronounced in SKOV3 (cf. Figure 3A, 
3C with Figure 3B, 3D). MALDI-MS/MS fragment ion 
analysis was used to determine the fatty acid composition 
of the individual PI species. Approximately 20 peaks 
representing the most prominent PI species are found in the 
mass range between m/z 800–920 (Supplementary Table 1 
and Supplementary Figure 3). Lipid species containing mainly 
Figure 1: The degrees of accumulation of malonyl-CoA and depletion of oleic acid (OA) upon inhibition of fatty acid 
synthase (FASN) in ovarian cancer (OC) cells depend on the particular inhibitors used. (A) Malonyl-CoA is quickly and 
strongly accumulated by G28UCM, but much less by C75. (B) Supplementation of OA, unlike PA, antagonizes C75-mediated growth 
inhibition more efficiently than G28UCM-mediated growth inhibition. Data obtained after exposure to C75 (80 µM for SKOV3 and 
HOC-7, 40 µM for OVCAR-3) or G28UCM (80 µM for SKOV3, 15 µM for OVCAR-3, 30 µM for HOC-7) ± 70 µM OA or PA are presented. 
1.5 × 10³ (SKOV3, OVCAR-3) or 0.5 × 10³ (HOC-7) cells/well were seeded in a 96 well plate and treated for 72 h. Note: In these 
experiments cultures contained bovine serum albumin (for details of dissolving fatty acids see Materials and methods), which lowers the 
efficacy of FASN-inhibitors [38]. Therefore, higher concentrations of C75 and G28UCM had to be applied in order to achieve marked 
inhibition of cell growth. Data from untreated controls (not shown in chart) were set to 100% and those from treated cultures were related 
to it. Means ± SD, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 FASN-inhibitor alone vs. FASN-inhibitor combined with OA or PA. One-way 
ANOVA and Scheffe-test. (C) C75 is a weak inducer of apoptosis compared to G28UCM. Moreover, OA fully abrogates C75-induced cell 
death, but only partially inhibits G28UCM-mediated apoptosis. Means ± SD, n = 3. **p < 0.01, ***p < 0.001 treated vs. untreated control 
(dashed horizontal line at y = 1). °°p < 0.01, °°°p < 0.001 FASN-inhibitor alone vs. FASN-inhibitor combined with OA or PA. One-way 
ANOVA and Scheffe-test. (D) Growth inhibition of OC cells after 72 h exposure to TOFA, an inhibitor of acetyl-CoA carboxylase. 
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OA (18:1(9Z)) are decreased, while those containing PUFAs 
like arachidonic acid (20 : 4 (5Z,8Z,11Z,14Z)) are increased 
after FASN-inhibition (Figure 3E, 3F). PI is precursor of all 
PI phosphates. Here we focus on PI 4-phosphate (PIP), PI 
4,5-bisphosphate (PIP2), and PI 3,4,5-trisphosphate (PIP3). 
These phospholipids control crucial steps in cancer cell 
signaling [25]. FASN-inhibitors elevate PIP and/or PIP2 
levels in SKOV3, but diminish them in OVCAR-3 cells 
(Figure 4A, 4B). Nevertheless, the drug-mediated changes 
of the FA composition of PIP2 are similar in both cell lines 
and correspond to those seen in PI, i.e. enrichment of PUFAs 
(e.g. arachidonic acid) and depletion of MUFAs (e.g. OA) 
(Figure 4C, 4D and Supplementary Figure 4). PI3K activates 
the PI3K-mTOR signaling cascade by phosphorylating PIP2 
to PIP3. Using a PIP3-specific ELISA we demonstrate that 
FASN-inhibitory drugs strongly diminish the cellular amount 
of PIP3 in OC cells (Figure 4E, 4F).
FASN-inhibitors impair GRB2 recruitment to 
the EGF receptor
Signal initiating molecules such as the epidermal 
growth factor (EGF) receptor (EGFR) tyrosine kinase 
are embedded in multi-molecular complexes that are 
anchored in membrane microdomains known as lipid 
rafts. FASN-blockade lowers the membrane lipid content. 
This leads to decomposition of the lipid rafts [26] and to 
reduced receptor phosphorylation [14]. Here we applied 
a live-cell micropatterning assay [27–29] to evaluate 
the role of FASN-blockade on recruitment of GRB2 to 
EGFR. SKOV3 cells co-expressing EGFR-CFP and 
GRB2-YFP were grown on anti-EGFR antibody coated 
micro-biochips and accumulation of GRB2 in EGFR-
microdomains was observed by total internal reflection 
fluorescence microscopy. Figure 5 reveals that EGF 
(17 nM, 15 min)-induced tethering of GRB2-YFP to 
EGFR-CFP is prevented not only by pretreatment with 
the EGFR-inhibitor AG1478 (10 µM, 4 h), but also by 
the FASN-inhibitors C75 and G28UCM. Decrease of the 
fluorescence contrast (c/c
0
) is already observed after 2 
hours and reaches statistical significance after 24 hours of 
treatment (Figure 5B).
HIF-1α/REDD1 and AMPK link FASN-blockade 
to mTORC1 suppression and growth inhibition
Western blotting was used to examine FASN-blocker-
mediated inhibition of PI3K-AKT-mTORC1. Thereby, 
we aimed to identify effector molecules that directly link 
FASN pathways to mTORC1. In SKOV3 cells treated with 
G28UCM we observed a rapid dose-dependent induction 
of HIF-1α and of its target gene, the stress response 
protein REDD1 (DDIT4, RTP801) (Figure 6A). Figure 7A 
reveals that blockade of HIF-1α with the specific inhibitor 
LW6 prevents G28UCM-mediated induction of REDD1 
indicating that REDD1 up-regulation is mediated by 
HIF-1α. Accordingly, both proteins accumulate within 
the first hour of FASN-inhibition. However, after 72 h, 
both HIF-1α and REDD1 are decreased relative to control 
cells (Figure 6A). Concurrently, phosphorylation of 
AMPK, which signifies shortage of bioenergy, becomes 
stimulated. Both REDD1 and pAMPK are repressors of 
mTORC1. Consequently, phosphorylation of the mTORC1 
effector ribosomal protein S6 is decreasing as soon as 
REDD1 is up-regulated and remains low due to ensuing 
suppression through pAMPK. Reduction of mTOR and of 
the mTOR binding partner DEPTOR has been observed 
after 2–3 days of treatment confirming robust impairment 
of the mTOR pathway (Figure 6A, 6B). Cleaved fragments 
of caspase 3 and PARP–two hallmarks of apoptosis–
occur approximately 24 h post-treatment. At that time 
mTORC1 activity has already been impaired (Figure 6A). 
Similar molecular changes are found in G28UCM-and 
C75-treated A2780 or OVCAR-3 cells (Supplementary 
Figure 5). Moreover, the effects are independent of the 
presence or absence of exogenous growth factors and can 
also be observed after RNAi knock-down of the FASN 
gene (Figure 6B and Supplementary Figure 6). Genetic 
knock-down of REDD1 or AMPKα1/2 reverts G28UCM-
mediated mTOR dephosphorylation and growth arrest 
Figure 2: Large fluctuations of DAG upon inhibition of FASN by G28UCM as demonstrated by thin-layer 
chromatography in SKOV3 (left) and OVCAR-3 (right). Values represent % change of total DAG in treated cells relative to 
untreated control cells (horizontal 0-line). Means ± SD, n = 3. *p < 0.05, **p < 0.01 vs. control cells, one-way ANOVA and Scheffe-test.
Oncotarget5www.impactjournals.com/oncotarget
(Figures 7B–7D). However, concurrent knock-down of 
both REDD1 and AMPKα1/2 does not yield stronger 
reversal of growth inhibition (Figure 7D). These data 
indicate that REDD1 and AMPK are interfering with the 
very same pathway, namely mTORC1, which essentially 
contributes to cell death. In contrast, carboplatin, a DNA-
cross linking chemotherapeutic drug with an unrelated 
mechanism of action, induces growth arrest and apoptosis, 
but does not elevate HIF-1α, REDD1 or pAMPKα, nor 
does it impede phosphorylation of S6 downstream of 
mTORC1 (Supplementary Figure 7).
Combining FASN-inhibitors with a MEK-inhibitor 
augments growth inhibition in OC cells
Inactivation of PI3K-mTORC1 is accompanied 
by compensatory stimulation of MAPK as evidenced by 
elevated levels of pERK after 1 and 2 days of treatment 
(Figure 6A, Supplementary Figure 5D). This FASN-
inhibitor-dependent loosening of PI3K-MAPK cross-
repression [30] prompted us to determine the effect 
of FASN-blockers combined with kinase inhibitors 
on OC cell growth. A large proportion of OC reveals 
hyper-activation of the PI3K-mTORC1 pathway [6]. 
Consequently, these cells are highly sensitive to dual 
PI3K-mTOR-inhibitors such as dactolisib/NVP-BEZ235, 
but not to MAPK pathway-inhibitors like MEK1/2-blocker 
selumetinib/AZD6244 (Figure 8A, 8B). Co-exposure to 
moderately effective doses of NVP-BEZ235 (0.2 µM in 
SKOV3 and 0.01 µM in A2780 and OVCAR-3) cannot 
improve the anticancer effect of the FASN-blockers 
(Figure 8A), whereas combination with AZD6244 (40 µM 
in SKOV3, 0.25 µM in A2780 and 3 µM in OVCAR-3) 
significantly increases the FASN-inhibitor sensitivity 
(Figure 8B). Accordingly, the IC
50
 values of G28UCM and 
C75 are significantly reduced in the presence of AZD6244, 
but not of NVP-BEZ235 (Figure 8C). This indicates that 
the mechanism of action of FASN-blockers is mediated 
through PI3K-mTORC1 inactivation. However, the anti-
proliferative efficacy of FASN-inhibitors is impaired by 
compensatory cross-induction of RAF-MEK-ERK.
DISCUSSION
Inhibition of FASN leads to FA depletion and 
accumulation of malonyl-CoA. The relative contribution 
of both events to FASN-inhibitor toxicity has been 
discussed [22, 31] and obviously depends on the type 
of inhibitor (Figure 1A–1C). Inhibitor-induced shortage 
of required reaction product can be uncoupled from 
Figure 3: FASN-inhibitors G28UCM and C75 down-regulate total phosphatidylinositol (PI) levels and alter the 
composition of individual PI species in SKOV3 (upper row-A, C, E) and OVCAR-3 (lower row-B, D, F) cells as 
demonstrated by MALDI-QIT-TOF-MS/MS analysis. (A, B) Time-course analyses revealed similar ‘bi-phasic response profiles’ 
of total PI in both cell lines with initial up-regulation at 8 h followed by sharp reductions at 24 and 72 h of exposure to G28UCM relative 
to untreated control cells (horizontal 0-line). (C, D) Long-term reduction of PI levels after 72 h treatment was less pronounced in SKOV3 
(C) than in OVCAR-3 cells (D). ISD internal lipid standards. (E, F) Similar drug-induced changes in the composition of individual PI 
species were seen after 72 h in both SKOV3 (E) and OVCAR-3 (F) cells including reduction of MUFAs (e.g. OA, 18:1) and enrichment 
of PUFAs (e.g. arachidonic acid, 20:4). C75 and G28UCM were applied at concentrations that block growth by 60–70% after 72 h 
(40 µM for SKOV3 and 20 µM for OVCAR-3) [16]. For further details see also Supplementary Table 1. Means ± SD, n = 3. *p < 0.05, 
**p < 0.01 vs. untreated control cells, one-way ANOVA and Scheffe-test. 
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inhibitor-induced buildup of toxic levels of substrate 
by blocking the upstream lipogenic enzyme acetyl-CoA 
carboxylase. This enzyme provides FASN with malonyl-
CoA. Therefore, Acetyl-CoA carboxylase-inhibitors 
such as TOFA cause FA depletion in the absence of high 
levels of malonyl-CoA [31]. Interestingly, TOFA reveals 
only low/moderate cytotoxicity in ovarian cancer cells 
(Figure 1D) suggesting that ,besides FA depletion, malonyl-
CoA elevation essentially contributes to the cytotoxicity of 
FASN-inhibitors. Nevertheless, supplementation of OA has 
been found to significantly alleviate growth inhibition by 
FASN-blockers and partially restores cancer cell survival, 
whereas supply of the primary enzyme product PA is rather 
toxic (Figure 1B, 1C). This indicates that availability of 
OA is crucial for sustained OC cell growth and that OC 
cells are not able to process exogenous PA properly. In 
addition, we observed that FASN-blockers alter the level 
of DAG and PI in an opposing biphasic manner. Early 
depletion of DAG concurs with a rise in PI followed by 
accumulation of DAG and reduction of PI. Eventually, the 
cells turn into a state of severe deficiency of both DAG 
and PI (cf. Figures 2 with 3A, 3B). This suggests that 
the drug-induced shortage of membrane phospholipids 
is initially balanced by intense conversion of DAG into 
PI. Eventually, however, the cells cannot prevent the 
lipid content to fall below a crucial threshold (see also 
Supplementary Figure S4). This stage is characterized 
by an ‘unsaturated’ membrane lipid phenotype, which is 
reflected by low MUFA-/high PUFA-content in PI and its 
phosphorylated derivatives. Previous studies have shown 
that cancer cell membranes in general tend to have a higher 
degree of saturation, thus rendering them more resistant to 
oxidative stress [32]. Hence, our study demonstrates that 
FASN-inhibition restores a membrane lipid phenotype that 
is reminiscent of non-malignant cells characterized by a 
low amount of saturated lipids.
FASN lies at the crossroads between catabolic and 
anabolic pathways. It controls homeostasis, energy balance 
and cell growth, and interacts with oncogenic signaling 
[22]. We recently observed that FASN-inhibition impairs 
ERBB-PI3K-mTORC1 signaling in OC [14, 15]. Yet, the 
underlying mechanism(s) remain elusive. Here we describe 
a number of events that lead to prompt inactivation of 
ERBB-PI3K-mTORC1 upon blockade of FA synthesis. 
Figure 4: The effects of FASN-inhibitors G28UCM and C75 on the phosphorylated derivatives of phosphatidylinositol 
[PIP = PI(4)P, PIP2 = PI(4,5)P2, PIP3 = PI(3,4,5)P3] in SKOV3 (upper row A, C, E) and OVCAR-3 (lower row B, D, 
F) cells as demonstrated by MALDI-QIT-TOF-MS/MS analysis using ‘internal lipid standards’ (ISD) for quantitative 
evaluation. (A, B) FASN-inhibition causes up-regulation of PIP and/or PIP2 in SKOV3 (A) but down-regulation in OVCAR-3 (B). 
(C, D) Yet, similar drug-induced changes in composition of PIP2 were seen in both cell lines including depletion of lipids containing 18 : 1 
and enrichment of those containing 20 : 4 fatty acids. The most prominent fatty acid residues esterified to the sn-2 position of the glycerol 
backbone of the PIP2 molecules are indicated. Culture conditions were as in Figure 3. (E, F) Exposure for 24 h to FASN-inhibitors C75, (-)
C75, or G28UCM down-regulates the amount of PIP3 in SKOV3 (E) and OVCAR-3 (F) cells relative to vehicle control (< 0.1% DMSO) as 
demonstrated by a competitive PIP3 mass ELISA. Means ± SD, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle control cells, one-way 
ANOVA followed by Scheffe test (A–D and F) or Student‘s t test (E).
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In particular, FASN-inhibition causes down-regulation of 
membrane phospholipids. It reduces the level of EGFR 
(ERBB)-receptor expression [14] and inhibits binding of 
GRB2 to EGFR (Figure 5B). This results in a decrease of 
signal activity upstream of PI3K. PIP2 is known to give rise 
to two signaling lipids: 1. DAG, which stimulates RAF and 
PI3K and 2. PIP3 generated by PI3K. These two lipids are 
located upstream and downstream of PI3K, respectively. 
We observed that FASN-inhibitory drugs down-regulate 
DAG corroborating previous data [20]. Moreover, we 
show for the first time that FASN-inhibitors lead to a 
significant deficit in PIP3 leading to inactivation of AKT-
mTORC1, which provides yet another cogent explanation 
for the observed FASN-inhibitor-dependent PI3K pathway 
suppression. Accordingly, mTORC1 downstream target 
ribosomal protein S6 becomes dephosphorylated. In 
addition, we observed that FASN-blockers activate cell 
stress proteins such as HIF-1α and REDD1, which are 
known to repress mTORC1. A similar REDD1 involvement 
has recently been observed when cells are exposed to 
the anti-lipogenic compound orlistat [32]. In our setup, 
up-regulation of REDD1 is transient and is followed by 
elevated pAMPK, another negative regulator of mTORC1, 
which gets activated when bioenergy is short. Quiescence 
Figure 5: FASN-inhibitors C75 and G28UCM counteract EGF-induced recruitment of GRB2 to EGFR. (A) Representative 
total internal reflection fluorescence microscopy images of a SKOV3 cell co-transfected with EGFR-CFP and GRB2-YFP and grown on an 
anti-EGFR antibody coated micro-biochip showing the specific recruitment of GRB2 to EGFR enriched regions after EGF stimulation (17 nM, 
15 min; lower row) relative to basal interaction (upper row). Scale bar = 9 µm. (B) Quantitative evaluation of the YFP fluorescence contrast 
reveals that pretreatment with FASN-inhibitors (40 µM, 0–48 h) counteracts EGF-induced binding of GRB2 to EGFR in SKOV3 cells. c/c
0
 
describes the ratio of YFP-fluorescence within (c) and between (c
0
) EGFR enriched regions. Error bars are based on the SE of > 15 analyzed 
cells from two individual experiments, respectively. *p < 0.05 vs. cells treated with EGF alone, one-way ANOVA and Scheffe-test.
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of PI3K-mTORC1 was found to precede FASN-inhibitor-
induced cleavage of caspase 3 and PARP, two markers 
of apoptosis. Accordingly, knockdown of either REDD1 
or AMPK renders phosphorylation/activity of mTOR 
(pmTOR) resistant to FASN-blockers and relieves drug-
induced growth inhibition (Figure 7B–7D). Attenuation 
of ERBB-PI3K-mTORC1 activity upon FASN blockade 
has been seen in all OC cell lines (SKOV3, A2780, 
OVCAR-3) independent of the mode of FASN inhibition 
(G28UCM, C75, FASN siRNAs) and independent of 
the presence or absence of ERBB-stimulating growth 
factors such as EGF and heregulin (HRG)-β1 (Figure 
6 and Supplementary Figures 5 and 6). In contrast, the 
standard cytotoxic drug carboplatin induces apoptosis 
without elevating HIF-1α, REDD1 or pAMPKα, and it 
does not diminish phosphorylation of S6 protein. This 
indicates that down-regulation of mTORC1-S6 activity 
is specifically required for apoptosis induction by FASN-
inhibitors but not by other drugs such as carboplatin. 
Combination of G28UCM or C75 with the dual PI3K/
mTOR inhibitor NVP-BEZ235 (Figure 8) or with statins 
(not shown), which inactivate mTORC1 as well [33], fails 
to strengthen the G28UCM- or C75-mediated anticancer 
response in SKOV3, A2780 or OVCAR-3 cells. This 
indicates FASN-inhibitor-mediated mTORC1 silencing is 
already maximal and additional blockade with yet another 
PI3K/mTOR inhibitor is not productive anymore. Recent 
evidence suggests that mTORC1-S6 activity may convert 
a reversible cell cycle arrest into an irreversible one, which 
typically occurs during cell senescence (geroconversion). 
Thus, in addition to its usual function as oncogenic driver, 
mTORC1-S6 may also act as inducer of cell aging when 
the cycle machinery has been halted by other means 
[34–36]. Phosphorylation of the MAPK ERK is increased 
when pAKT levels drop. Most likely, this is due to release 
of PI3K-AKT cross-inhibition of RAF-MEK-ERK. 
Accordingly, concurrent blockade of the MEK-ERK axis 
by MEK1/2 inhibitors such as AZD6244 or by upstream 
ErbB inhibitors [14] increase the sensitivity against 
FASN-blockers. Thus FASN-blocker-mediated decrease 
Figure 6: Pharmacologic inhibition or genetic knock-down of FASN impedes PI3K-mTORC1 signaling and induces 
apoptosis in OC cells as demonstrated by Western blot analysis. (A) G28UCM-treated SKOV3 cells reveal early upregulation 
of HIF-1α and REDD1 and concurrent inhibition (de-phosphorylation) of the mTORC1 downstream effector ribosomal S6 protein (pS6). 
Subsequently, REDD1 and pAKT become decreased, whereas pAMPKα gets increased. Levels of pERK peak at 24–48 h. Cleavage products 
of caspase 3 and PARP1 indicating apoptosis occur after 24 h of treatment. ‘-‘ First indication of down-regulation, ‘+’ first indication of 
up-regulation. OD optical density of specific band relative to actin band normalized to untreated control cells (0 µM G28UCM). (B) FASN 
siRNAs abrogate FASN protein expression in A2780 cells 72 h post-transfection and down-regulate HIF-1α, REDD1, pmTOR, mTOR, 
pp70S6K, p4EBP1, and 4EBP1, whereas levels of pAMPKα, pERK1/2, ERK1/2, and cleaved PARP increase. Actin was used as loading 
control. ◄ cleaved PARP.
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of PI3K-mTORC1 signaling results in untightening of 
cross-inhibition of MAPK thereby enabling compensatory 
MAPK activation, which lowers the anticancer effect of 
FASN-blocking agents. Further clinical development and 
evaluation of combinations of FASN-targeting drugs with 
MAPK pathway inhibitors are therefore warranted.
MATERIALS AND METHODS
Cell culture and drugs
OC cell lines HOC-7 (R.N. Buick, Toronto, 
Canada), OVCAR-3, SKOV3 (ATCC, Manassas, VA) and 
A2780 (M. Krainer, Medical University Vienna, Austria) 
were maintained in α-MEM or RPMI1640 [37]. Media 
were supplemented with 10% fetal calf serum (FCS), 
100 IU (µg)/ml penicillin-streptomycin and 2 mM glutamine 
(Gibco, Karlsruhe, Germany). Cells were maintained at 
37°C, 5% CO
2
 and 95% humidity and were tested for 
absence of viral/bacterial/fungal/mycoplasmal infection 
(Venor GeM, Minerva Biolabs, Berlin, Germany). The 
species origins were proven by species-PCR, and cell 
line identities were examined by fluorescent nonaplex-
PCR of short tandem repeat markers in summer of 2014 
(DSMZ, Braunschweig, Germany). PA (16:0) and OA 
(18:1(9Z))(Sigma, St. Louis, MO) dissolved in ethanol 
were complexed with bovine serum albumin in Dulbecco’s 
phosphate buffered saline [38] and diluted in growth media 
Figure 7: HIF-1α-mediated up-regulation of REDD1 and phosphorylation of AMPKalpha(greek symbol) are 
crucial for the anticancer effect of FASN-inhibitors in OC cells as demonstrated by Western blot analysis 
(A–C) and formazan dye assay (D). (A) The HIF-1α inhibitor LW6 prevents G28UCM-mediated up-regulation of HIF-
1α and REDD1. SKOV3 (left) or A2780 (right) cells received 2 or 10 µM LW6 for 18 h followed by a 6 h-exposure to 40 or 
20 µM G28UCM, respectively. (B, C) REDD1-(B), AMPKα1- and AMPKα2-specific siRNAs (C) dampen the expression of their respective 
target genes and (B) prevent G28UCM-mediated (40 µM, 4 h) down-regulation of pmTOR in SKOV3 and A2780 cells. OD, optical density 
of specific band relative to actin band normalized to untreated control cells. (D) siRNA knock-down of REDD1 or AMPKα1,2 alone or 
together is lowering the growth inhibitory effect of G28UCM (40 µM, 96 h) in SKOV3 and A2780 cells. Means ± SD, n = 3. *p < 0.05, 
**p < 0.01 target siRNA vs. control siRNA, one-way ANOVA followed by Scheffe test.
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to final concentration of 70 µM. Recombinant human EGF 
and heregulin-β1 (HRG) were purchased from Sigma and 
Thermo Fisher Scientific (Fremont, CA), respectively. EGFR 
inhibitor AG1478 (Calbiochem, San Diego, CA), PI3K/
mTOR dual blocker dactolisib/NVP-BEZ235, MEK1/2 
inhibitor selumetinib/AZD6244 (ChemieTek, Indianapolis, 
Figure 8: The effect of the dual PI3K/mTOR kinase inhibitor dactolisib/NVP-BEZ235 and of the MEK1/2 kinase 
inhibitor selumetinib/AZD6244 on the anti-proliferative effects of the FASN-blockers G28UCM and C75 as 
demonstrated by formazan dye assay. SKOV3, A2780 or OVCAR-3 cells were treated for 72 h with NVP-BEZ235 (A) or AZD6244 
(B) alone (left charts), or with G28UCM (center charts) or C75 (right charts) alone or together with NVP-BEZ235 or AZD6244. A circle 
symbol as given in the original manuscript and in the corresponding diagrams marks the fixed concentration of the kinase inhibitors chosen 
for combination with various doses of the FASN-inhibitors. In (C) a comparison of the relative IC
50
 values of the FASN-blockers G28UCM 
and C75 in the absence (arbitrarily set at y = 1) or presence of NVP-BEZ235 (BEZ) or AZD6244 (AZD) is given. Note: only AZD6244 can 
significantly lower the IC
50
 values of the FASN-inhibitors G28UCM and C75 (←). Means ± SD, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 
presence (AZD) vs. absence of AZD6244 (−), one-way ANOVA followed by Scheffe test. 
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IN), HIF-1α inhibitor LW6 (Calbiochem), FASN-inhibitors 
C75 (racemic mixture of (−)- and (+)-enantiomers, Sigma), 
(−)-C75 (F.G. Hegardt, D. Serra, Barcelona, Spain) [39], 
G28UCM (R. Colomer, M.L. López Rodríguez, Madrid, 
Spain) [40, 41] and TOFA (Calbiochem) were dissolved in 
DMSO, whereas carboplatin (Selleckchem, Houston, TX) 
was dissolved in sterile water. Stocks were diluted 1:500 or 
1:1 000 in media.
Malonyl-CoA assay
SKOV3 cells (2 × 104/cm²) exposed for 0–72 h to 
40 µM C75 or G28UCM were lysed in ice-cold lysis buffer 
(20 mM MOPS, pH 7.0; 2 mM EGTA; 5 mM EDTA; 1% 
Triton X-100), sonicated (4 strokes at median amplitude, 
10 sec each, 4°C) and centrifuged (1 500 × g, 15 min, 
4°C). The supernatants containing 1.3 mg protein were 
subjected to the Malonyl CoA BioAssay ELISA following 
manufacturer’s instructions (United States Biological, 
Salem, MA).
Cell proliferation
Cells (500–3 000/well, 96-well plate) attached 
overnight before media containing 5% FCS ± drugs were 
added. Cell numbers were determined using a formazan 
dye assay (Biomedica, Vienna, Austria) as described [42].
Apoptosis assay
SKOV3 cells (2 × 104/cm²) attached overnight 
before media containing 5% FCS ± drugs were added. 
At the end of treatment, cells were trypsinized and 
counted. Ten thousand cells per sample were lysed in 
proprietary lysis buffer and further processed for detection 
of apoptosis using the Cell Death Detection ELISAplus 
system from Roche Diagnostics GmbH (Vienna, Austria) 
following the manufacturer’s protocol.
Lipid extraction and thin-layer chromatography
A modified two-step organic solvent extraction 
protocol [43] was used to enrich PIs and PIPs. Briefly, 
cold CHCl3 :MeOH (50:50 [v/v]) added to the washed 
cell pellet, vortexed and centrifuged (2 000 × g, 5 min) 
yielded a supernatant designated ‘Extract 1’. The cell 
pellet was extracted again with CHCl3 : MeOH (70:30 
[v/v], containing 0.3% aqueous HCl), sonicated (15–30 
sec) and vortexed (5 min). 1N HCl was added, vortexed 
(1–2 min) and centrifuged (12 000 × g, 5 min). The lower 
organic phase represents ‘Extract 2’. This procedure 
leads to efficient separation of > 85% PI in ‘Extract 1’ 
and > 95% PIP and PIP2 in ‘Extract 2’ (Supplementary 
Figure 8). For thin-layer chromatography, aliquots of 
both extracts were pooled and the lipids were separated 
as described [16].
Mass spectrometry (MS)
Mass spectra were recorded using an AXIMA-
CFRplus (Shimadzu, Manchester, UK) curved-field 
reflectron TOF mass spectrometer equipped with a 
337-nm pulsed nitrogen laser in the negative mode 
using 9-aminoacridine as matrix [44]. Ion acceleration 
voltage was 20 kV and the reflectron analyzer was at 
25 kV. For structural identification of lipid molecules 
a hybrid quadrupole iontrap (QIT)-TOF tandem-mass 
spectrometer (MS/MS; AXIMA-Resonance, Shimadzu) 
was used. Acquisition was in the low-mass range (m/z 
300–1 000) and high-resolution (R = 1 000) ion selection 
modes for MS/MS experiments of monoisotopically 
selected precursor ions using low-energy collision 
induced dissociation with argon as the collision gas. 
Each spectrum shown represents the accumulation of 
300–500 single laser shots. An external calibration based 
on the exact mass values of the [M-H]- ions of defined 
lipid standards was applied. The structural identity of 
the different lipid species detected in the samples was 
confirmed by MALDI-MS/MS spectra of authentic 
reference compounds (Supplementary Figure 9). Data 
processing was performed by Launchpad 2.9.3 software 
(Shimadzu) using the Savitzky-Golay smoothing 
algorithm. 
PIP3 mass ELISA
PIP3, unlike PIP and PIP2, was not amenable to MS 
analysis–probably due to the high negative charge of PIP3 
causing co-segregation with the protein fraction. This lipid 
had therefore to be analyzed with a different technology. 
SKOV3 and OVCAR-3 cells plated at 2.5 × 106 and 
5 × 106, respectively, in 150 mm dishes were grown in 
α-MEM containing 5% FCS and treated for 24 h with 
the indicated concentrations of the FASN-inhibitors. For 
detection of PI3K activity the cellular amount of its reaction 
product PIP3 was directly quantitated using a competitive 
PIP3 mass ELISA system following the manufacturer’s 
protocol (Echelon, Salt Lake City, UT). Thereby PIP3 
extracted from 107 cells is first incubated with a PIP3-
detector protein. The PIP3/PIP3-detector protein-complex 
is then added to a PIP3-coated microplate for competitive 
binding. A peroxidase-linked secondary reagent and a 
colorimetric substrate are used to visualize the PIP3-
detector protein bound to the plate. The colorimetric signal 
is inversely proportional to the amount of PIP3 extracted 
from the cells.
Micropatterning assay
For detection and quantitation of the effects of 
FASN-inhibition on GRB2 recruitment to the membrane-
bound EGFR signaling complex a protocol applying 
micropatterning followed by total internal reflection 
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fluorescence microscopy and image analysis was executed 
as described [19, 27–29].
Western blotting
Cells plated in media containing 5% FCS were 
treated with solvent (0.1% DMSO) in the absence or 
presence of various concentrations of FASN-inhibitor 
for 1 to 72 h. After lysis, proteins were subjected to 
SDS–PAGE, blotted and immunostained as described 
[45, 46] using anti-FASN (BD Biosciences, San Jose, 
CA; 1:500), anti-AKT, anti-pAKT, anti-AMPKα, 
anti-pAMPKα, anti-DEPTOR, anti-ERK, anti-pERK, 
anti-HIF-1α, anti-mTOR, anti-pmTOR, anti-p70S6K, 
anti-pp70S6K, anti-S6, anti-pS6, anti-4EBP1, anti-
p4EBP1, anti-cleaved caspase 3, anti-PARP1 (Cell 
Signaling Technology, Boston, MA; 1 : 500–1:3 000), 
anti-REDD1 (Proteintech, Manchester, UK; 1:1 000), 
and anti-actin (Santa Cruz Biotechnology, Dallas, TX; 
1:1 000). Secondary antibodies were peroxidase-labelled 
donkey-anti-rabbit (Promega, Madison, WI) or donkey-
anti-goat IgG (Santa Cruz Biotechnology) at  1:15 000, 
or chicken-anti-mouse IgG (Santa Cruz Biotechnology) at 
1:10 000. Detection was by enhanced chemiluminescence.
RNA interference
A2780 or SKOV3 cells were transiently transfected 
with 75 nM of FASN-, REDD1- and/or AMPKα1- and 
AMPKα2-siRNAs according to the manufacturer’s 
instructions (Dharmacon, Lafayette, CO). Briefly, 
3 × 105 cells/35-mm dish were incubated in DharmaFECT-3 
siRNA lipid transfection reagent either containing 
corresponding concentrations of siGENOME non-
targeting siRNA #2 (D-001210-02) or containing a set of 
4 siRNA species, each at a concentration of 18.75 nM, that 
target the mRNA of FASN or of the mTORC1 upstream 
repressors REDD1, AMPKα1, or AMPKα2, respectively 
(ON-TARGETplus SMARTpool FASN, L-003954-00; 
ON-TARGETplus SMARTpool REDD1, L-010855-01; 
ON-TARGETplus SMARTpool AMPKα1, L-005027-00; 
ON-TARGETplus SMARTpool AMPKα2,L-005361-00). 
Cells were cultured for 72 h at 37°C, 5% CO
2
, and 95% 
humidity in RPMI-1640 or α-MEM containing 5% FCS 
and 2 mM glutamine. FASN siRNA-transfectants were 
directly lysed, whereas the other transfectants were 
cultured and exposed for 96 h to 0.1% DMSO (vehicle) 
or 40 µM G28UCM and then subjected to a formazan dye 
cell proliferation assay (see above). Moreover, short-term 
(4 h) vehicle- or 40 µM G28UCM-treated transfectants 
were lysed and processed for SDS-PAGE and Western 
blotting to demonstrate efficient knockdown of baseline 
and FASN-inhibitor-induced target protein expression 
and its stabilizing effect on mTOR phosphorylation (see 
above). Data were obtained from unselected polyclonal 
transfectant populations.
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